DCGO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
DocGo Inc. is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading near its short-term support area, but the bigger picture remains weak: revenue fell sharply in the latest quarter, margins compressed, and net losses widened materially. With no strong bullish proprietary signal, no recent news catalyst, and analyst views still mixed-to-cautious, the current setup is more of a watchlist name than a buy.
DCGO is in a weak technical position. MACD histogram is below zero and expanding negatively, which points to continued downside momentum. RSI_6 at 37.5 is neutral-to-weak, not yet oversold enough to signal a strong rebound. Moving averages are converging, suggesting compression rather than a confirmed uptrend. Price at 0.6324 is sitting just above S1 support at 0.625 and below the pivot at 0.673, so the stock is trading in the lower part of its range. Near-term pattern data suggests only modest upside over a month, but weakness over the next week. Overall trend: bearish to neutral, not a strong buy setup.
["Canaccord noted that the formal process exploring strategic alternatives could deliver a positive outcome for shareholders.", "Stifel highlighted improving growth in the transportation segment and raised 2026 guidance modestly.", "The stock is trading near S1 support, which could attract short-term value interest."]
["No news in the recent week, so there is no fresh event-driven catalyst.", "Revenue in 2025/Q4 dropped 37.98% YoY.", "Gross margin fell to 27.25%, down 11.44% YoY.", "Net income was -134.1M, with losses widening sharply year over year.", "Canaccord cut its price target to $1 from $1.50 and kept Hold, maintaining a cautious 'show me' stance.", "No recent hedge fund accumulation, insider buying, or congress trading activity was reported.", "The company has an earnings release on 2026-05-11 after hours, which may keep sentiment cautious until results are known."]
In 2025/Q4, DocGo showed deteriorating operating performance. Revenue declined to 74.94M, down 37.98% YoY, while gross margin fell to 27.25% from a year earlier. Net income was -134.07M, a very large loss and sharply worse than last year, and EPS came in at -1.37. The latest quarter season was Q4 2025, and the financial trend is negative overall, with shrinking sales and weaker profitability.
Analyst sentiment is mixed but leaning cautious. Canaccord lowered its price target to $1 and kept Hold, citing mixed Q4 results and the need to scale Mobile Health and improve profitability. Stifel remained more constructive, cutting its target to $2.50 from $4 but keeping Buy, pointing to better transport growth and potential value in the transport unit. Overall, Wall Street sees possible asset or strategic value, but the fundamentals still need proof before a strong bullish case can be made.
